Fingolimod Completed Phase 4 Trials for Multiple Sclerosis / Disorders of the Autonomic Nervous System Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science4
clinicaltrials.gov IdentifierTitleDrugs
NCT02048072Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS